• Consensus Rating: Moderate Buy
  • Consensus Price Target: $108.67
  • Forecasted Upside: 22.59%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.45 (-1.61%)

This chart shows the closing price for HAE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haemonetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HAE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HAE

Analyst Price Target is $108.67
▲ +22.59% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $108.67, with a high forecast of $125.00 and a low forecast of $94.00. The average price target represents a 22.59% upside from the last price of $88.64.

This chart shows the closing price for HAE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Haemonetics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$115.00 ➝ $125.00Low
5/10/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$105.00 ➝ $107.00Low
5/10/2024Needham & Company LLCReiterated RatingHoldLow
4/12/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$105.00Low
2/13/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$105.00Low
11/3/2023Barrington ResearchLower TargetOutperform ➝ Outperform$114.00 ➝ $105.00Low
10/2/2023CitigroupBoost TargetNeutral ➝ Neutral$90.00 ➝ $94.00Low
8/9/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$111.00 ➝ $114.00Low
5/12/2023Barrington ResearchBoost Target$103.00 ➝ $111.00Low
5/12/2023JMP SecuritiesBoost Target$105.00 ➝ $115.00Low
4/3/2023CitigroupLower Target$95.00 ➝ $90.00Low
2/8/2023CitigroupBoost TargetNeutral$92.00 ➝ $95.00Low
2/8/2023Morgan StanleyBoost TargetEqual Weight$84.00 ➝ $88.00Low
2/8/2023Barrington ResearchBoost TargetOutperform$94.00 ➝ $103.00Low
2/8/2023MizuhoBoost TargetBuy$110.00 ➝ $115.00Low
1/24/2023MizuhoBoost TargetBuy$100.00 ➝ $110.00Low
1/6/2023Morgan StanleyLower TargetEqual Weight$90.00 ➝ $84.00Low
12/12/2022CitigroupBoost TargetNeutral$88.00 ➝ $92.00Low
11/8/2022Morgan StanleyBoost TargetEqual Weight$85.00 ➝ $90.00Low
11/8/2022Barrington ResearchBoost TargetOutperform$88.00 ➝ $94.00Low
11/8/2022Raymond JamesBoost TargetOutperform$88.00 ➝ $100.00Low
11/8/2022JMP SecuritiesBoost TargetMarket Outperform$90.00 ➝ $105.00Low
11/8/2022MizuhoBoost TargetBuy$90.00 ➝ $100.00Low
11/8/2022CitigroupBoost TargetNeutral$80.00 ➝ $88.00N/A
10/12/2022MizuhoInitiated CoverageBuy$90.00Low
10/11/2022Morgan StanleyBoost TargetEqual Weight$74.00 ➝ $85.00Low
10/5/2022CitigroupBoost Target$74.00 ➝ $80.00Low
8/15/2022CitigroupBoost Target$74.00N/A
8/11/2022Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $74.00Low
8/11/2022JMP SecuritiesBoost TargetMarket Outperform$80.00 ➝ $90.00Low
8/11/2022Barrington ResearchBoost TargetOutperform$77.00 ➝ $88.00Low
8/11/2022Raymond JamesBoost TargetOutperform$76.00 ➝ $88.00Low
7/8/2022JMP SecuritiesReiterated RatingBuy$80.00N/A
7/1/2022Morgan StanleyBoost TargetEqual Weight$60.00 ➝ $70.00Low
7/1/2022Raymond JamesBoost TargetOutperform$63.00 ➝ $76.00Low
6/2/2022JMP SecuritiesReiterated RatingBuy$80.00High
5/11/2022Barrington ResearchBoost Target$71.00 ➝ $77.00High
2/9/2022Barrington ResearchReiterated RatingOutperformMedium
2/9/2022Raymond JamesLower TargetOutperform$70.00 ➝ $66.00Low
1/27/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
1/7/2022Morgan StanleyLower TargetEqual Weight$68.00 ➝ $60.00Low
12/15/2021CitigroupDowngradeBuy ➝ Neutral$75.00 ➝ $59.00High
11/10/2021JMP SecuritiesLower TargetOutperform$90.00 ➝ $80.00Medium
11/10/2021Raymond JamesLower TargetOutperform$75.00 ➝ $70.00Medium
6/29/2021Needham & Company LLCReiterated RatingBuy$86.00Low
6/17/2021CitigroupInitiated CoverageBuyHigh
5/20/2021JMP SecuritiesLower TargetMarket Outperform$110.00 ➝ $90.00Low
5/14/2021Jefferies Financial GroupLower TargetBuy$105.00 ➝ $85.00High
5/14/2021CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
5/14/2021Barrington ResearchLower TargetOutperform$91.00 ➝ $71.00High
5/14/2021Morgan StanleyLower TargetEqual Weight$83.00 ➝ $75.00High
5/14/2021JMP SecuritiesLower TargetOutperform$110.00 ➝ $90.00High
4/26/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$147.00 ➝ $83.00N/A
4/20/2021Barrington ResearchLower TargetOutperform$140.00 ➝ $91.00High
4/20/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$147.00 ➝ $83.00High
4/19/2021Needham & Company LLCLower TargetBuy$158.00 ➝ $108.00High
4/19/2021CJS SecuritiesDowngradeOutperform ➝ Market PerformHigh
2/12/2021Raymond JamesBoost TargetOutperform$145.00 ➝ $155.00Low
2/3/2021Morgan StanleyBoost TargetOverweight$139.00 ➝ $147.00Low
2/3/2021Raymond JamesBoost TargetOutperform$135.00 ➝ $145.00Low
2/3/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$140.00Low
1/21/2021JMP SecuritiesBoost Target$110.00 ➝ $140.00Medium
1/21/2021Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
1/20/2021Needham & Company LLCBoost TargetBuy$122.00 ➝ $142.00Medium
1/7/2021Raymond JamesBoost TargetOutperform$130.00 ➝ $135.00N/A
12/15/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $139.00Low
11/5/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$106.00High
11/2/2020Raymond JamesBoost TargetOutperform$100.00 ➝ $130.00Low
9/15/2020Barrington ResearchReiterated RatingHoldLow
9/8/2020Raymond JamesBoost TargetOutperform$93.00 ➝ $100.00Medium
8/5/2020Raymond JamesLower TargetOutperform$113.00 ➝ $93.00Low
8/4/2020Needham & Company LLCReiterated RatingBuy$119.00Low
7/8/2020Morgan StanleyLower TargetOverweight$138.00 ➝ $110.00Medium
7/1/2020Raymond JamesLower TargetOutperform$125.00 ➝ $113.00Low
5/29/2020Needham & Company LLCInitiated CoverageBuy$132.00Low
5/6/2020Raymond JamesLower TargetOutperform$130.00 ➝ $125.00High
5/6/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
5/5/2020Needham & Company LLCLower TargetBuy$142.00 ➝ $132.00High
4/7/2020Raymond JamesLower TargetOutperform$150.00 ➝ $130.00High
3/31/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
3/27/2020Morgan StanleyLower TargetOverweight$148.00 ➝ $138.00Low
2/5/2020Raymond JamesBoost TargetOutperform$145.00 ➝ $150.00High
2/4/2020Needham & Company LLCReiterated RatingBuy$142.00High
1/23/2020Raymond JamesLower TargetOutperform$150.00 ➝ $145.00High
1/10/2020Needham & Company LLCInitiated CoverageBuy$138.00Low
11/4/2019Barrington ResearchReiterated RatingBuy$141.00Low
8/7/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$116.00 ➝ $139.00Low
8/7/2019Morgan StanleyBoost TargetOverweight$128.00 ➝ $148.00Low
8/7/2019Raymond JamesBoost TargetOutperform$110.00 ➝ $150.00Low
8/7/2019JMP SecuritiesBoost TargetOutperform$145.00Low
8/2/2019Jefferies Financial GroupBoost TargetBuy$125.00 ➝ $140.00Low
(Data available from 5/23/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 14 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 16 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 28 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 28 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $88.64
Low: $87.86
High: $91.00

50 Day Range

MA: $87.25
Low: $74.78
High: $97.37

52 Week Range

Now: $88.64
Low: $70.74
High: $97.97


2,458,220 shs

Average Volume

488,774 shs

Market Capitalization

$4.51 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Haemonetics?

The following equities research analysts have issued research reports on Haemonetics in the last twelve months: Barrington Research, Citigroup Inc., JMP Securities, Needham & Company LLC, StockNews.com, and TheStreet.
View the latest analyst ratings for HAE.

What is the current price target for Haemonetics?

3 Wall Street analysts have set twelve-month price targets for Haemonetics in the last year. Their average twelve-month price target is $108.67, suggesting a possible upside of 23.6%. JMP Securities has the highest price target set, predicting HAE will reach $125.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $94.00 for Haemonetics in the next year.
View the latest price targets for HAE.

What is the current consensus analyst rating for Haemonetics?

Haemonetics currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HAE.

What other companies compete with Haemonetics?

How do I contact Haemonetics' investor relations team?

Haemonetics' physical mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier's listed phone number is (781) 848-7100 and its investor relations email address is [email protected]. The official website for Haemonetics is www.haemonetics.com. Learn More about contacing Haemonetics investor relations.